BRAF and melanoma: Here, we demonstrated that synthetized triphenyl phosphonium cationic nano vesicles (BPPB), which have been previously found to be effective on two populations of BRAF mutant metastatic melanoma cells still sensitive to PLX (MeOV BRAFV600E and MeTRAV BRAFV600D cells), are effective also on the PLX-R counterpart of cells (PLX-R MeOV BRAFV600E and MeTRAV BRAFV600D cells) at nanomolar concentrations after 48 and 72 h of treatment.